Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Single-dose, 6-Period, 8-Sequence Crossover Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Subjects Under Fasted and Semi-fasted Conditions
Conditions
Interventions
Seltorexant 40 mg
Seltorexant 20 mg
Locations
1
United States
PRAHS
Salt Lake City, Utah, United States
Start Date
February 9, 2018
Primary Completion Date
May 30, 2018
Completion Date
May 30, 2018
Last Updated
April 27, 2025
NCT06716502
NCT06290258
NCT07310264
NCT00090662
NCT07483606
NCT07310901
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions